| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
CASI Pharmaceuticals (NASDAQ:CASI) reported its Q4 earnings results on Thursday, March 28, 2024 at 07:00 AM.
Here's what investors need to know about the announcement.
CASI Pharmaceuticals missed estimated earnings by -88.0%, reporting an EPS of $-0.45 versus an estimate of $-0.24.
Revenue was down $8.38 million from the same period last year.
Last quarter the company beat on EPS by $0.21 which was followed by a 3.0% drop in the share price the next day.
Here's a look at CASI Pharmaceuticals's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.56 | -0.50 | -0.64 | -0.37 |
| EPS Actual | -0.35 | -0.77 | -0.45 | -1.44 |
| Revenue Estimate | 10.40M | 10.09M | 9.10M | 10.79M |
| Revenue Actual | 8.84M | 9.82M | 8.35M | 15.26M |
To track all earnings releases for CASI Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CASI
